Effect of ICS/LABA combination in an ex vivo model of COPD exacerbation Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020
Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
CTLA4-Ig enhanced glucocorticoid effect on murine asthma Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017
MIF antagonism restores corticosteroid sensitivity in a murine model of severe asthma Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018
Roflumilast inhibits chemokine release in animal models of COPD and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
A novel receptor antagonist, c-027, inhibits airway contraction in human and murine models of allergen, independent of inflammatory mediator release Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
Characterisation of an ex vivo model of human airway epithelium Source: International Congress 2019 – Novel insights from in vitro and in vivo models of lung disease Year: 2019
Dose dependent effect of thrombomodulin in a murine model of allergen-induced asthma Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012
Effect of human neutrophil proteases on ex vivo small airway function Source: Annual Congress 2013 –Stress responses and T-cell behaviour in the lung Year: 2013
Effect of ligustrazine inhalation on the expression of stem cells factor (SCF) in mouse asthma models Source: Eur Respir J 2007; 30: Suppl. 51, 361s Year: 2007
Effect of muscarinic receptors inhibition on cytokine release and inflammatory cells infiltration in the airway of cat as an animal model for COPD Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012
Local inhibition of IL-4 and IL-13 protects lung function in OVA mouse model Source: Annual Congress 2011 - Animal models of airway inflammation Year: 2011
Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021
Acupuncture regulates macrophage polarization in COPD mice model by activating dopamine D2 receptor. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Murine models of asthma Source: Eur Respir J 2003; 22: 374-382 Year: 2003
Novel approach to prevention of dust-induced acute lung injury with interleukin-1 receptor antagonist (IL-1ra) Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015